An Alternative Splice Form of Mdm2 Induces p53-independent Cell Growth and Tumorigenesis
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The Mdm2 gene is amplified in approximately one-third of human sarcomas and overexpressed in a variety of other human cancers. Mdm2 functions as an oncoprotein, in part, by acting as a negative regulator of the p53 tumor suppressor protein. Multiple spliced forms of Mdm2 transcripts have been observed in human tumors; however, the contribution of these variant transcripts to tumorigenesis is unknown. In this report, we isolate alternative splice forms of Mdm2 transcripts from sarcomas that spontaneously arise in Mdm2-overexpressing mice, including Mdm2-b, the splice form most commonly observed in human cancers. Transduction of Mdm2-b into a variety of cell types reveals that Mdm2-b promotes p53-independent cell growth, inhibits apoptosis, and up-regulates the RelA subunit of NFkappaB. Furthermore, expression of Mdm2-b induces tumor formation in transgenic mice. These results identify a p53-independent role for Mdm2 and determine that an alternate spliced form of Mdm2 can contribute to formation of cancer via a p53-independent mechanism. These findings also provide a rationale for the poorer prognosis of those patients presenting with tumors harboring multiple Mdm2 transcripts.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, Mdm2 also has p53-independent activities, and the pathways that mediate these functions are unresolved.”
From Mdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair (2005) · cites this paper as [33]
In the citing paper
“Combined, these reports suggest that Mdm2 has functions independent of p53 that contribute to transformation.”
From Mdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair (2005) · cites this paper as [33]
Citations
Cites
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Self-citationMomand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Wang, C.-Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., & Baldwin, A. S. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,711
NF-κB in cancer: from innocent bystander to major culprit
Karin, M., Cao, Y., Greten, F. R., & Li, Z.-W. (2002) · Nature Reviews Cancer · doi:10.1038/nrc780 · Cited by 2,478
Gewirtz, D. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00307-4 · Cited by 2,240
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,451
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
mdm2 expression is induced by wild type p53 activity.
Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280
Self-citationMdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53
Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H., & Weissman, A. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8945 · Cited by 1,044
Regulation of Receptor Fate by Ubiquitination of Activated β 2 -Adrenergic Receptor and β-Arrestin
Shenoy, S. K., McDonald, P. H., Kohout, T. A., & Lefkowitz, R. J. (2001) · Science · doi:10.1126/science.1063866 · Cited by 824
The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B.
Schmitz, M. L., & Baeuerle, P. A. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb04950.x · Cited by 796
Role of NF-κB in p53-mediated programmed cell death
Ryan, K. M., Ernst, M. K., Rice, N. R., & Vousden, K. H. (2000) · Nature · doi:10.1038/35009130 · Cited by 740
ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage
Maya, R., Balass, M., Kim, S.-T., Shkedy, D., Leal, J.-F. M., Shifman, O., Moas, M., Buschmann, T., Ronai, Z., Shiloh, Y., et al. (2001) · Genes & Development · doi:10.1101/gad.886901 · Cited by 731
Mapping of the p53 and mdm-2 interaction domains.
Chen, J., Marechal, V, & Levine, A. J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.7.4107 · Cited by 689
Wang, C.-Y., Guttridge, D. C., Mayo, M. W., & Baldwin, A. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.5923 · Cited by 590
Interaction between the retinoblastoma protein and the oncoprotein MDM2
Xiao, Z.-X., Chen, J., Levine, A. J., Modjtahedi, N., Xing, J., Sellers, W. R., & Livingston, D. M. (1995) · Nature · doi:10.1038/375694a0 · Cited by 587
Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E., & Collins, V. P. (1993) · PubMed · Cited by 560
NF-κB, chemokine gene transcription and tumour growth
Richmond, A. (2002) · Nature Reviews Immunology · doi:10.1038/nri887 · Cited by 523
(1994) · PubMed · Cited by 509
Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein
Martin, K., Trouche, D., Hagemeier, C., Sorensen, T. S., La Thangue, N. B., & Kouzarides, T. (1995) · Nature · doi:10.1038/375691a0 · Cited by 454
Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis
Jones, S. N., Hancock, A. R., Vogel, H., Donehower, L. A., & Bradley, A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15608 · Cited by 386
Self-citationCahilly-Snyder, L., Yang-Feng, T., Francke, U., & George, D. L. (1987) · Somatic Cell and Molecular Genetics · doi:10.1007/bf01535205 · Cited by 355
The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.
Finlay, C. A. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.1.301 · Cited by 311
The human MDM-2 oncogene is overexpressed in leukemias
Bueso-Ramos, C., Yang, Y., deLeon, E., McCown, P., Stass, S., & Albitar, M. (1993) · Blood · doi:10.1182/blood.v82.9.2617.2617 · Cited by 291
Sigalas, I., Calvert, A. H., Anderson, J. J., Neal, D. E., & Lunec, J. (1996) · Nature Medicine · doi:10.1038/nm0896-912 · Cited by 268
Lundgren, K., Montes de Oca Luna, R., McNeill, Y. B., Emerick, E. P., Spencer, B., Barfield, C. R., Lozano, G., Rosenberg, M. P., & Finlay, C. A. (1997) · Genes & Development · doi:10.1101/gad.11.6.714 · Cited by 235
Induction of Nuclear Factor κB by the CD30 Receptor Is Mediated by TRAF1 and TRAF2
Duckett, C. S., Gedrich, R. W., Gilfillan, M. C., & Thompson, C. B. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.3.1535 · Cited by 216
Self-citationAlternative and aberrant splicing of MDM2 mRNA in human cancer
Bartel, F., Taubert, H., & Harris, L. C. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00091-0 · Cited by 195
Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice
Weissenberger, J., Steinbach, J. P., Malin, G., Spada, S., Rülicke, T., & Aguzzi, A. (1997) · Oncogene · doi:10.1038/sj.onc.1201168 · Cited by 176
Tip60 is targeted to proteasome‐mediated degradation by Mdm2 and accumulates after UV irradiation
Legube, G., Linares, L. K., Lemercier, C., Scheffner, M., Khochbin, S., & Trouche, D. (2002) · The EMBO Journal · doi:10.1093/emboj/21.7.1704 · Cited by 165
Ser326Cys polymorphism inhOGG1 gene and risk of esophageal cancer in a Chinese population
Xing, D.-Y., Tan, W., Song, N., & Lin, D. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010520)95:3<140::aid-ijc1024>3.0.co;2-2 · Cited by 161
An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2
Evans, S. C., Viswanathan, M., Grier, J. D., Narayana, M., El‐Naggar, A. K., & Lozano, G. (2001) · Oncogene · doi:10.1038/sj.onc.1204533 · Cited by 153
Malek, S., Huxford, T., & Ghosh, G. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.39.25427 · Cited by 153
The Mdm2 Oncoprotein Interacts with the Cell Fate Regulator Numb
Juven-Gershon, T., Shifman, O., Unger, T., Elkeles, A., Haupt, Y., & Oren, M. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3974 · Cited by 140
Gu, L., Findley, H. W., & Zhou, M. (2002) · Blood · doi:10.1182/blood.v99.9.3367 · Cited by 127
c-Abl Neutralizes the Inhibitory Effect of Mdm2 on p53
Sionov, R. V., Moallem, E., Berger, M., Kazaz, A., Gerlitz, O., Ben-Neriah, Y., Oren, M., & Haupt, Y. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8371 · Cited by 104
Matsumoto, R., Tada, M., Nozaki, M., Zhang, C. L., Sawamura, Y., & Abe, H. (1998) · PubMed · Cited by 104
The RING domain of Mdm2 can inhibit cell proliferation.
Dang, J., Kuo, M.-L., Eischen, C. M., Stepanova, L., Sherr, C. J., & Roussel, M. F. (2002) · PubMed · Cited by 99
A Novel Cellular Protein (MTBP) Binds to MDM2 and Induces a G1 Arrest That Is Suppressed by MDM2
Boyd, M. T., Vlatkovic, N., & Haines, D. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004252200 · Cited by 94
Brenner, M., & Messing, A. (1996) · Methods · doi:10.1006/meth.1996.0113 · Cited by 90
Jones, S. N., Sands, A. T., Hancock, A. R., Vogel, H., Donehower, L. A., Linke, S. P., Wahl, G. M., & Bradley, A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14106 · Cited by 87
Self-citationBartel, F., Meye, A., W�rl, P., Kappler, M., Bache, M., Lautenschl�ger, C., Gr�nbaum, U., Schmidt, H., & Taubert, H. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010520)95:3<168::aid-ijc1029>3.0.co;2-a · Cited by 78
de Toledo, S. M., Azzam, E. I., Dahlberg, W. K., Gooding, T. B., & Little, J. B. (2000) · Oncogene · doi:10.1038/sj.onc.1204020 · Cited by 76
Identification and Characterization of Nuclear Factor κB Binding Sites in the Murine bcl‐χ Promoter
Glasgow, J. N., Wood, T., & Perez‐Polo, J. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751377.x · Cited by 73
MDM2 and MDMX inhibit the transcriptional activity of ectopically expressed SMAD proteins.
Yam, C. H., Siu, W. Y., Arooz, T., Chiu, C. H. S., Lau, A. W. S., Wang, X. Q., & Poon, R. Y. C. (1999) · PubMed · Cited by 46
Grand, R. J. A., Lecane, P. S., Owen, D., Grant, M. L., Roberts, S., Levine, A. J., & Gallimore, P. H. (1995) · Virology · doi:10.1006/viro.1995.1349 · Cited by 28
Genomic organization of the mouse double minute 2 gene
Jones, S. N., Ansari-Lari, M. A., Hancock, A. R., Jones, W. J., Gibbs, R. A., Donehower, L. A., & Bradley, A. (1996) · Gene · doi:10.1016/0378-1119(96)00151-5 · Cited by 21
Self-citation
Research works printed but not linked: 7
- Finlay, 1993, Mol. Cell. Biol., 13, 301
- Chen, 1993, Mol. Cell. Biol., 13, 4107
- Reifenberger, 1993, Cancer Res., 53, 2736
- Cordon-Cardo, 1994, Cancer Res., 54, 794
- Yam, 1999, Cancer Res., 59, 5075
- Matsumoto, 1998, Cancer Res., 58, 609
- Dang, 2002, Cancer Res., 62, 1222
Cited by
The gene encoding the splicing factor SF2/ASF is a proto-oncogene
Karni, R., de Stanchina, E., Lowe, S. W., Sinha, R., Mu, D., & Krainer, A. R. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1209 · Cited by 934
“Many other genes that are involved in proliferation and invasiveness are alternatively spliced, and specific isoforms that contribute to the transformed phenotype are frequently elevated in tumor”
BackgroundThe Mdm2–p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor
Manfredi, J. J. (2010) · Genes & Development · doi:10.1101/gad.1941710 · Cited by 344
“Although full-length Mdm2 was used for expression in certain transgenic models, examination of Mdm2 in resulting tumors showed that the Mdm2 can be truncated (Steinman et al. 2004).”
BackgroundThe Roles of MDM2 and MDMX in Cancer
Karni-Schmidt, O., Lokshin, M., & Prives, C. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040349 · Cited by 296
Alternative splicing: an emerging topic in molecular and clinical oncology
Pajares, M. J., Ezponda, T., Catena, R., Calvo, A., Pio, R., & Montuenga, L. M. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70104-3 · Cited by 267
Tisato, V., Voltan, R., Gonelli, A., Secchiero, P., & Zauli, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0500-5 · Cited by 256
Metadata
- Authors
- Steinman, H. A., Burstein, E., Lengner, C., Gosselin, J., Pihan, G., Duckett, C. S., & Jones, S. N.
- Affiliations
- University of Michigan (US)
- University of Massachusetts Chan Medical School (US)
- Corresponding author
- Jones, Stephen N.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-02
- Volume
- 279
- Issue
- 6
- Pages
- 4877-4886
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2151665323
- Cited by
- 96
- References
- 51
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 3 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 7 · 2016: 8 · 2015: 3 · 2014: 6 · 2013: 6 · 2012: 8
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6077 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship@UMassChan (submittedVersion)
- Funders
- National Cancer Institute (CA 77735)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK032520)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- MDM2, alternative splicing, sarcoma, carcinogenesis, cell growth, apoptosis inhibition, NF-κB RelA, transgenic mice
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Cell Division, Humans, Mice, Transgenic, Molecular Sequence Data, Nuclear Proteins, Proto-Oncogene Proteins, Sarcoma, Experimental, Transfection, Tumor Suppressor Protein p53, Apoptosis, Sequence Homology, Amino Acid, Alternative Splicing, DNA, Complementary, NIH 3T3 Cells, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.